Canopy Growth (CGC) and Tilray Brands (TLRY) represent the two largest publicly traded cannabis companies in Canada, each pursuing a distinct path forward.
The cannabis market continues shifting as companies move beyond pure-play cultivation toward diversified consumer brand strategies that reduce exposure to volatile marijuana prices.
Canopy Growth has chosen a more focused route, concentrating on Canadian adult-use markets and expanding its presence in the growing German medical cannabis segment.
In fiscal year 2026, Canopy Growth reported revenue of approximately $203.2 million, reflecting growth of nearly 5.8% compared to the prior year, a modest but meaningful improvement.
Despite that revenue progress, the company posted a net loss of close to $187.7 million, translating to a deeply negative net margin of roughly 92.4%, highlighting how far it remains from profitability.
Canopy is actively working to narrow those losses and has targeted positive EBITDA by the end of its current fiscal year, which investors will be watching closely.
Tilray Brands has taken a markedly different approach, aggressively diversifying into craft beverages and wellness products to reduce its dependence on unpredictable cannabis pricing dynamics.
Tilray’s fiscal 2026 revenue reached approximately $915.5 million, representing an increase of about 11% year over year, making it a substantially larger operation than Canopy by revenue scale.
The company reported a net loss of $105.2 million for the period, translating to a net margin of roughly negative 11.5%, a far less severe position than Canopy’s comparable figure.
Tilray also generated $61.1 million in adjusted EBITDA for 2026, up 11%, and the company is projecting adjusted EBITDA of between $68 million and $75 million for the full year of 2027.
On valuation, Canopy Growth trades at a price-to-sales ratio of 1.9x, while Tilray Brands carries a lower P/S ratio of just 0.5x, reflecting the market’s assessment of each company’s growth prospects.
Tilray’s lower P/S ratio and more favorable forward P/E based on future earnings estimates position it as the more attractively valued of the two stocks at current prices.
U.S. federal cannabis legalization remains out of reach for now, which continues to cap the upside available to pure-play cannabis operators relying on a regulatory breakthrough to unlock growth.
Tilray’s pivot toward acquiring a substantial U.S. craft beverage footprint has helped cushion it against the ongoing uncertainty surrounding cannabis regulation at the federal level.
Investors drawn to portfolio diversification and a clearer road to profitability may find Tilray’s model more compelling, while those betting specifically on cannabis trade growth might look more closely at Canopy’s focused strategy.
